, but also in district general hospitals (Editorial, 1978) (Turner, 1978a) and the place of pharmacokinetics in therapeutics clarified (Dollery, 1973 ). An important factor that has contributed towards this change of emphasis has been the development of acceptable and safe methodology, much of it non-invasive, to measure drug responses in man (e.g. Shanks, 1979) .
During the past decade the concept of 'individualization' of drug dosage has received considerable emphasis (Koch-Weser, 1975) , and therapeutic drug monitoring is an integral part of this in the use of phenytoin, quinidine, theophylline, lithium and aminoglycoside antibiotics. Routine monitoring may also be justified in some patients receiving other anticonvulsant and antidysrhythmic drugs and, possibly, some monoamine re-uptake inhibiting ('tricyclic') antidepressant drugs (Richens and Warrington, 1979 ). An important limitation to this, however, is the problem of considerable inter-and intra-laboratory variation in quality of accuracy of drug analysis, and quality control schemes have, therefore, been set up in an attempt to reduce this variability and improve the standard of patient care (Richens, 1978) .
Improved and more sophisticated methods for estimation of drugs and their metabolites have permitted an increase over the last decade in our understanding of factors influencing drug distribution in the body, including blood flow, clearance, plasma and tissue binding, and route of administration (Shand, 1978) . receptor agonism and antagonism for a variety of transmitter substances.
The classifications of adrenoceptors by Ahlquist (1948) and Lands et al. (1967) was extended by the realization of the importance of pre-as well as postsynaptic receptors which modulate transmitter release (Langer, 1977) . This, together with the demonstration of central nervous adrenoceptors concerned with the control of sympathetic outflow, has made possible a better understanding of the mechanisms of action of some antihypertensive drugs such as clonidine and methyldopa (Davies and Reid, 1976) . The mechanism of the antihypertensive action of 3-adrenoceptor blocking drugs is still not clear, although a variety have been suggested (Turner, 1978b) . It is unlikely that a central mechanism is important in this action, although the central effect of 3-blocking drugs has attracted much interest, not only because of their therapeutic actions in tremor, anxiety and migraine, but also because of claims for an antipsychotic effect (Turner, 1979 (Parkes, Debono and Marsden, 1976) . The potent prolactin-secretion inhibiting effect of bromocriptine has also permitted further elucidation of the role of dopamine in controlling prolactin release (Mashiter et al., 1977) . Dopamine has also attracted much interest through its actions on the heart and peripheral vasculature, particularly its dilator effects in the renal arterial system (Goldberg and Weder, 1980) . A major advance in the past decade has been the introduction of a histamine 2-receptor blocking drug, cimetidine, for clinical use. Its place in the management of peptic ulcer and other gastrointestinal conditions is still being assessed, but it has already permitted some evaluation of the role of H2 receptors in other systems, including the central nervous and cardiovascular systems (Langman, 1980 (Davies and Lefkowitz, 1980; Turner, 1980 Greenacre, Schofield and Conolly, 1978) .
Prostaglandins and prostacyclin
The importance of the prostaglandin, thromboxane and prostacyclin derivatives of arachidonic acid in physiology and in many different pathological states is now well known, and has been the subject of many reviews. Bennett (1978) has reviewed the evidence for their involvement in atherosclerosis and other forms of peripheral vascular disease, metastatic spread of breast cancer, hypercalcaemia, patency of ductus arteriosus, gastro-oesophageal reflux, druginduced gastric bleeding, diarrhoea from radiation and endotoxins, and Bartter's syndrome, as well as the exciting hypothesis that some non-steroidal anti-inflammatory drugs such as aspirin and indomethacin act by inhibiting prostaglandin synthesis.
The discovery of prostacyclin (PGI2) has fundamentally altered our understanding of thrombosis and haemostasis (O'Grady, 1980) , and there is already some exciting evidence that it may be involved in toxaemia of pregnancy (Lewis et al., 1980) and in systemic sclerosis (Kirby et al., 1980) .
Peptide transmitters in the central nervous system
Although the peptide substance P was discovered in the brain and other tissues by Von Euler and Gaddum in 1931, the importance of peptides as putative neurotransmitters has only really emerged during the past decade, so that Snyder (1980) has now listed more than 20 and even thinks there may be more than 200. Radioimmunoassay and immunocytochemical techniques have shown that some peptides first identified in the gut wall, such as vasoactive intestinal polypeptide (VIP) and cholecystokinin are also found in the brain. Releasing and release-inhibiting factors first identified in the hypothalamus, such as thyrotrophin releasing hormone (TRH) and somatostatin have been found to have wider central nervous distribution (Sweet, 1980; Editorial, 1980) . Limited human studies and much animal evidence suggest that these peptides have roles in the control of behaviour, emotions, sex and sleep. Vasopressin appears to have some potential to stimulate memory in some patients with dementia, and it may be involved in the therapeutic action of lithium in affective disorders (Gold, Goodwin and Reus, 1978 (Tregear and Coghlan, 1980) . There is evidence that they may be involved in the flushing that occurs in some chlorpropamide-treated subjects after consuming alcohol (Leslie, Pyke and Stubbs, 1979) . It is tempting to see a relationship between their possible role in the chlorpropamide-alcohol syndrome in diabetics and the effect of morphine on blood glucose levels (Feldberg and Smyth, 1977) .
